Q2 2026 saw 32% year-over-year growth in core test volumes and revenue guidance raised to $365–375M. Adjusted gross margin was 76.3% and adjusted EBITDA reached $12.4M, with strong cash reserves and continued clinical adoption across segments.Original document: Castle Biosciences, Inc. [CSTL] Slide…
Q2 2026 saw 32% year-over-year growth in core test volumes and revenue guidance raised to $365–375M. Adjusted gross margin was 76.3% and adjusted EBITDA reached $12.4M, with strong cash reserves and continued clinical adoption across segments.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
